Paul Kramer, MD
Family Medicine · Roseville, CANPI 1790794048
Payments from drug & device makers
Across 290 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$753
- GSK$713
- Lilly USA, LLC$632
- Pfizer$608
- Novo Nordisk$366
- Sanofi-aventis U.S. LLC$338
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,055100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $753 |
| GSK | 39 | $713 |
| Lilly USA, LLC | 30 | $632 |
| Pfizer | 43 | $608 |
| Novo Nordisk | 20 | $366 |
| Sanofi-aventis U.S. LLC | 26 | $338 |
| Amgen | 14 | $235 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $228 |
| Exact Sciences | 8 | $173 |
| AstraZeneca | 8 | $151 |
| Boehringer Ingelheim | 7 | $143 |
| Amarin Pharma, Inc. | 4 | $77 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $64 |
| Phathom Pharmaceuticals, Inc. | 4 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $57 |
| Merck | 3 | $56 |
| Bayer | 2 | $47 |
| Biodelivery Sciences International, Inc. | 3 | $45 |
| Antares Pharma, Inc. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Eisai Inc. | 2 | $30 |
| Azurity Pharmaceuticals, Inc. | 1 | $28 |
| Vertex | 1 | $28 |
| Novartis | 1 | $25 |
| Almatica Pharma LLC | 1 | $24 |
| Johnson & Johnson | 1 | $21 |
| Abbott | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
How this compares
$5,072 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 151 | $162,112 |
| MounjaroTirzepatide | 99 | $160,675 |
| TrulicityDulaglutide | 74 | $133,244 |
| JardianceEmpagliflozin | 97 | $132,902 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $71,468 |
| OzempicSemaglutide | 42 | $65,221 |
| JanuviaSitagliptin Phosphate | 31 | $40,994 |
| XareltoRivaroxaban | 25 | $32,747 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $23,561 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $23,062 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $19,562 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $13,404 |
| CreonLipase/Protease/Amylase | 12 | $10,737 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $10,367 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 269 | $9,924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $632 | $293,919173 claims |
| PfizerEliquis | $608 | $162,112151 claims |
| Boehringer IngelheimJardiance | $143 | $132,90297 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $713 | $101,488154 claims |
| Novo NordiskOzempic | $366 | $65,22142 claims |
| MerckJanuvia, Janumet | $56 | $60,55650 claims |
| Johnson & JohnsonXarelto | $21 | $32,74725 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $338 | $23,06223 claims |
| AbbVieCreon, Synthroid | $753 | $16,83698 claims |
| AstraZenecaSymbicort | $151 | $4,28117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Roseville
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.